

Supplementary Table 1. Pooled relative risks (RRs) and 95% confidence intervals (CIs) for combined *GSTM1*, *GSTT1*, or *NAT2* genotype and regular genital talc use history and ovarian cancer risk in the New England Case-Control Study (NECC) and the Nurses' Health Study (NHS)*[†]

	Total epithelial ovarian cancer			Serous invasive ovarian cancer		
	No regular talc	Regular talc	<i>P</i> -interaction [‡]	No regular talc	Regular talc	<i>P</i> -interaction [‡]
<i>GSTM1</i>						
<i>GSTM1</i> present (+)	1.0 (ref.)	1.6 (1.2, 2.1)		1.0 (ref.)	2.0 (1.5, 2.8)	
Cases/controls	480/646	189/165		173/546	90/135	
<i>GSTM1</i> null (-)	1.0 (0.8, 1.1)	1.2 (0.9, 1.5)	0.13	1.1 (0.8, 1.3)	1.4 (1.0, 2.0)	0.05
Cases/controls	498/690	179/198		190/566	76/165	
<i>GSTT1</i>						
<i>GSTT1</i> present (+)	1.0 (ref.)	1.2 (1.0, 1.5)		1.0 (ref.)	1.5 (1.2, 2.0)	
Cases/controls	785/1035	278/301		288/867	129/247	
<i>GSTT1</i> null (-)	0.9 (0.7, 1.1)	1.7 (1.2, 2.4)	0.03	0.9 (0.6, 1.2)	1.9 (1.2, 2.9)	0.17
Cases/controls	194/300	87/67		71/246	38/57	
<i>NAT2</i>						
<i>NAT2</i> rapid/intermediate acetylator	1.0 (ref.)	1.5 (1.1, 2.1)		1.0 (ref.)	1.9 (1.2, 2.8)	
Cases/controls	330/459	128/113		123/393	57/92	
<i>NAT2</i> slow acetylator	0.9 (0.6, 1.2)	1.1 (0.6, 1.9)	0.60	0.9 (0.7, 1.2)	1.4 (1.0, 2.0)	0.57
Cases/controls	552/819	217/233		204/661	96/192	
<i>GSTM1</i> / <i>GSTT1</i> genotype						
<i>GSTM1</i> +, <i>GSTT1</i> +	1.0 (ref.)	1.4 (1.0, 1.9)		1.0 (ref.)	1.8 (1.2, 2.6)	
Cases/controls	378/479	142/140		136/406	68/112	
<i>GSTM1</i> -, <i>GSTT1</i> +	0.9 (0.8, 1.1)	1.0 (0.8, 1.4)		1.0 (0.8, 1.3)	1.3 (0.9, 1.9)	
Cases/controls	400/541	135/154		151/454	60/131	
<i>GSTM1</i> +, <i>GSTT1</i> -	0.8 (0.6, 1.1)	2.6 (1.1, 6.1)		0.8 (0.5, 1.2)	2.7 (1.4, 5.2)	
Cases/controls	98/158	47/24		34/135	22/23	
<i>GSTM1</i> -, <i>GSTT1</i> -	0.8 (0.5, 1.2)	1.2 (0.7, 2.2)	0.03	0.9 (0.6, 1.5)	1.4 (0.7, 2.6)	0.10
Cases/controls	94/138	40/41		36/108	16/33	

*Unconditional (NECC) and conditional (NHS) logistic regression adjusted for age, study center (NECC only), duration of oral contraceptive use (months), parity (continuous), tubal ligation, body mass index (kg/m², continuous), and duration of postmenopausal hormone use (months)

[†]*P*-values for tests for heterogeneity comparing the NECC and NHS results were all >0.22, except the *p*-values for the *NAT2* slow acetylator genotype and risk of total ovarian cancer, which were >0.08

[‡]*P*-values for interaction based on likelihood ratio test comparing unconditional logistic regression models with and without gene-talc interaction terms